× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
     
button bars forest bayes pooled summary
Treament Trials
Demonstrated or suggested benefit Inconclusive results Uncertain results Safety results
14

demonstrated 14 % decrease in deaths

suggested 10 % increase in hospital discharge

inconclusive results for: deaths (time to event analysis only); clinical deterioration; clinical improvement; clinical improvement (14-day); clinical improvement (time to event analysis only); death or ventilation; ventilation; serious adverse events; superinfection--
6

demonstrated 32 % increase in clinical improvement

suggested 49 % increase in clinical improvement (14-day)

suggested 64 % increase in clinical improvement (28-day)

suggested 29 % increase in clinical improvement (7-day)

suggested 29 % decrease in serious adverse events

suggested 42 % decrease in elevated liver enzymes

inconclusive results for: deaths; deaths (time to event analysis only); clinical improvement (time to event analysis only); death or ventilation; ventilation; AE leading to drug discontinuation; deep vein thrombosis; hyperbilirubinemia; pulmonary embolism; renal impairment--
35 noneinconclusive results for: deaths; deaths (time to event analysis only); clinical deterioration; clinical improvement; clinical improvement (14-day); clinical improvement (28-day); clinical improvement (time to event analysis only); death or ventilation; PCR-negative conversion; PCR-negative conversion (14-day); PCR-negative conversion (time to event analysis only); radiologic improvement (7-day); ventilation; ventilation (time to event analysis only); ICU admission; cardiac arrest; abnormal ECG findings; adverse events; arrhythmia--
17

demonstrated 52 % decrease in clinical deterioration

inconclusive results for: death or transfer to ICU; deaths; deaths (time to event analysis only); clinical improvement; clinical improvement (28-day); death or ventilation; PCR-negative conversion (7-day); ventilation; ICU admission; off oxygenation; serious adverse events--
8

demonstrated 3.4-fold increase in clinical improvement (time to event analysis only)

inconclusive results for: deaths; clinical improvement; death or ventilation; hospital discharge; PCR-negative conversion (time to event analysis only); ventilation; ICU admission--
18

demonstrated 25 % increase in clinical improvement

demonstrated 38 % decrease in death or ventilation

inconclusive results for: death or transfer to ICU; deaths; deaths (time to event analysis only); clinical deterioration; clinical improvement (28-day); clinical improvement (time to event analysis only); hospital discharge; ventilation; ICU admission; superinfection--
6

demonstrated 76 % increase in clinical improvement

inconclusive results for: deaths; deaths (time to event analysis only); death or ventilation; ventilation; off oxygenation--
6

suggested 94 % increase in clinical improvement (14-day)

inconclusive results for: death or transfer to ICU; deaths; clinical deterioration; clinical improvement; clinical improvement (28-day); clinical improvement (7-day); clinical improvement (time to event analysis only); hospital discharge; PCR-negative conversion; PCR-negative conversion (14-day); PCR-negative conversion (7-day); PCR-negative conversion (time to event analysis only); radiologic improvement (14-day); radiologic improvement (7-day); serious adverse events--
3 noneinconclusive results for: deaths; clinical deterioration; ventilation--
6

demonstrated 82 % decrease in ICU admission

inconclusive results for: deaths; death or ventilation; PCR-negative conversion--
1 none---

Demonstrated: statistically demonstrated that is statistically significant with a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons